Abstract
This research aimed to estimate whether first-time anxiety diagnoses and medication usage during and after the COVID-19 pandemic differed from diagnosis and medication usage rates prior to the COVID-19 pandemic, within groups stratified by age. We observed a significant increase in first-time anxiety diagnoses and prescriptions for 12–17-year-olds during April 2020-March 2021 compared to January 2018-February 2020. These trends were not sustained in subsequent periods. We also observed an increase in first-time prescriptions for 18–29-year-olds during the same time. The study emphasizes the importance of addressing mental health concerns, particularly among adolescents, both during and beyond the pandemic.
Competing Interest Statement
All authors were/are employees of Truveta, Inc.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Normalized electronic health record data are de-identified by expert determination under the HIPAA Privacy Rule before being made available to researchers. In accordance with 46.101 Protection of Human Subjects, our study did not require Institutional Review Board approval because it used only deidentified medical records. All data used in this study are publicly available to Truveta subscribers and may be accessed at studio.truveta.com.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data used in this study are available to all Truveta subscribers and may be accessed at studio.truveta.com.